BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20671419)

  • 1. New insights for development of a safe and protective RSV vaccine.
    Blanco JC; Boukhvalova MS; Shirey KA; Prince GA; Vogel SN
    Hum Vaccin; 2010 Jun; 6(6):482-92. PubMed ID: 20671419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.
    Yin W; Li HY; Zheng BY; Deng YQ; Li WJ; Liu Y; Zeng RH
    Curr Med Sci; 2019 Jun; 39(3):363-370. PubMed ID: 31209804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.
    Russell MS; Creskey M; Muralidharan A; Li C; Gao J; Chen W; Larocque L; Lavoie JR; Farnsworth A; Rosu-Myles M; Hashem AM; Yauk CL; Cao J; Van Domselaar G; Cyr T; Li X
    Front Immunol; 2019; 10():597. PubMed ID: 30984178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
    van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
    J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
    Lindell DM; Morris SB; White MP; Kallal LE; Lundy PK; Hamouda T; Baker JR; Lukacs NW
    PLoS One; 2011; 6(7):e21823. PubMed ID: 21789184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.
    Graham BS
    Immunol Rev; 2011 Jan; 239(1):149-66. PubMed ID: 21198670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
    Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccines against respiratory syncytial virus.
    Yang K; Varga SM
    Curr Opin Virol; 2014 Jun; 6():78-84. PubMed ID: 24794644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.
    González PA; Bueno SM; Riedel CA; Kalergis AM
    Curr Med Chem; 2009; 16(34):4609-25. PubMed ID: 19903147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
    Jorquera PA; Anderson L; Tripp RA
    Expert Rev Vaccines; 2016; 15(2):173-87. PubMed ID: 26641318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.
    Hwang HS; Lee YT; Kim KH; Ko EJ; Lee Y; Kwon YM; Kang SM
    Virology; 2017 Nov; 511():142-151. PubMed ID: 28846899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
    Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
    Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells.
    Wang Y; Ge F; Wang J; Li H; Zheng B; Li W; Chen S; Zheng X; Deng Y; Wang Y; Zeng R
    J Virol; 2023 Mar; 97(3):e0176422. PubMed ID: 36779760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.